Search clinical trials for: Antiparkinson Agents

Total 186955 results

University of Chicago

Recruiting

A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder

Obsessive-Compulsive Disorder | OCD

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

Neural Substrates in Nicotine Withdrawal

Tobacco Use Disorder

United States
Orion Corporation, Orion Pharma

Completed

Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.

Parkinson's Disease

Germany
Region Skane
Lund University

Recruiting

Pramipexole for Anhedonic Depression (PRIME-PRAXOL)

Depression | Anhedonia | Psychiatric Disorders Mood

Sweden
Massachusetts General Hospital
European Leukodystrophy Association

Recruiting

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Restless Legs Syndrome | Adrenoleukodystrophy

United States, Netherlands
Knopp Biosciences
Biogen

Terminated

Phase 3 Extension Study of Dexpramipexole in ALS (ENVISION)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Netherlands, Spain, Belgium, Germany, Australia, Sweden, France, Ireland, Canada
Sherief Abd-Elsalam

Unknown

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Diabetes

Egypt
Boehringer Ingelheim

Completed

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Restless Legs Syndrome
Boehringer Ingelheim

Completed

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

Parkinson Disease
Boehringer Ingelheim

Completed

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

Restless Legs Syndrome

Austria, Belgium, Finland, Germany, Ireland, Netherlands, Slovakia, Spain, United Kingdom
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

United States, Austria, Czech Republic, Finland, France, Germany, Hungary, India, Japan, Malaysia, Netherlands, Russian Federation, Slovakia, Taiwan, Ukraine
University of Aarhus

Completed

Cabergoline as a Preventive Treatment for Chronic Migraine

Migraine

Denmark
University of Utah

Completed

Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease

Parkinson Disease | Orthostatic Hypotension

United States
Novartis

Completed

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

Parkinson's Disease

United States
Wen-Hann Tan
Baylor College of Medicine; University of California, San Francisco; Vanderbilt... and other collaborators

Completed

A Trial of Levodopa in Angelman Syndrome

Angelman Syndrome

United States
Acorda Therapeutics

Completed

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Idiopathic Parkinson's Disease

United States, Austria, Belgium, Czechia, France, Germany, Hungary, Israel, Netherlands, Poland, Romania, Serbia, Spain, United Kingdom
Acorda Therapeutics

Completed

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Idiopathic Parkinson's Disease

United States, Italy, Serbia, United Kingdom
Pfizer

Completed

A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Restless Legs Syndrome

Austria, Germany, Switzerland, Sweden
University of Chicago

Completed

Tolcapone Treatment of Pathological Gambling

Pathological Gambling

United States
Northwell Health
Stanley Medical Research Institute

Completed

Cognitive Enhancement in Bipolar Disorder

Bipolar Disorder

United States
Boehringer Ingelheim

Completed

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Restless Legs Syndrome
Abbott Products

Terminated

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

Advanced Stage Parkinson's Disease

Germany, Italy, Portugal
Region Skane
Lund University

Completed

Pramipexole to Target "Anhedonic Depression" (PILOT-PRAXOL)

Anhedonia | Depression, Unipolar | Dysthymia | Depression, Bipolar

Sweden
Kissei Pharmaceutical Co., Ltd.

Completed

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms

Depression | Parkinson Disease

Austria, Finland, France, Germany, Italy, Netherlands, Norway, Romania, Russian Federation, South Africa, Spain, Sweden, Ukraine
Boehringer Ingelheim

Completed

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Parkinson Disease

United States
Seoul National University Hospital

Unknown

Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)

Parkinson's Disease

Korea, Republic of
Desitin Arzneimittel GmbH

Completed

SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease (PIR-001/K)

Parkinson's Disease
Desitin Arzneimittel GmbH

Completed

SEDPARK2: Post Marketing Surveillance to Observe Safety and Efficacy of Piribedil in Parkinson's Disease (PIR-002/K)

Parkinson's Disease

Germany
Par Pharmaceutical, Inc.
Anapharm

Completed

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

To Determine Bioequivalence Under Fasting Conditions

Canada
University Hospital, Geneva

Recruiting

Effect of Dopamine on Specific Processing of Shame and Embarrassment in Parkinson's Disease (BioDopa)

Parkinson Disease

Switzerland
GlaxoSmithKline

Terminated

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

Restless Legs Syndrome

Japan
GlaxoSmithKline

Completed

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

Restless Legs Syndrome

United States, Canada
GlaxoSmithKline

Completed

Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164

Parkinson Disease

United States
National Institute of Mental Health (NIMH)

Recruiting

PET Scanning in Parkinson s Disease

Schizophrenia | Parkinson's Disease

United States
Instituto Valenciano de Infertilidad, IVI VALENCIA

Completed

Cabergoline Reduces OHSS

Ovarian Hyperstimulation Syndrome
Areteia Therapeutics

Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) (EXHALE-3)

Asthma | Eosinophilic Asthma | Asthma; Eosinophilic

United States, South Africa, United Kingdom, Korea, Republic of
Areteia Therapeutics

Recruiting

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. (EXHALE-2)

Asthma | Eosinophilic Asthma | Asthma; Eosinophilic

United States, United Kingdom, Georgia, Romania, Brazil, Bulgaria, Korea, Republic of, Poland, Serbia, Argentina
Oregon Health and Science University
University of Southern California; Forest Laboratories; University of Texas Southwestern... and other collaborators

Completed

Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Multiple Sclerosis | Cognition Disorders

United States
Boehringer Ingelheim

Completed

Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

Parkinson Disease

Austria
Northwestern University
Lynn Sage Foundation

Completed

Cabergoline in Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Acorda Therapeutics

Completed

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Idiopathic Parkinson's Disease

United States, Canada, Czechia, Poland, Spain
GlaxoSmithKline

Completed

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Parkinson's Disease | Parkinson Disease

United States, Spain, Poland, France, Belgium, Hungary, United Kingdom, Italy, Czech Republic
Orion Corporation, Orion Pharma

Completed

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens (PARTEST)

Parkinson's Disease

Finland, Sweden
University of Buenos Aires
Laboratorios Phoenix S.A.I.C.y F.

Completed

Fasting Comparative Bioavailability of Two Tablet Formulations of Levodopa /Benserazide in Healthy Volunteers (PHOE10903)

Healthy Volunteers
Yale University
National Institute on Drug Abuse (NIDA); US Department of Veterans Affairs

Completed

Treatment for Nicotine Addiction in Women

Nicotine Dependence

United States

Search clinical trials for: Antiparkinson Agents

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations